Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC

Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC is a phase 2, interventional study registered as NCT06555133 by Brown University, with a registry enrolment figure of 18 participants, started 2025-04-07 and due to reach its primary completion in 2026-09-01. Interventions recorded: yttrium-90 radioembolization. Conditions listed: Colorectal Carcinoma Metastatic in the Liver. Primary outcome: To assess the preliminary efficacy with the combination of yttrium-90, capecitabine, and atezolizumab based on the intrahepatic disease control rate (iDCR) at 12 weeks. Colorectal eligibility wording from the registry: "Histologically confirmed diagnosis of colorectal adenocarcinoma". Sites: United States. No results are recorded here; the registry entry is the source.